Unlocking the Future of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market: Growth Rate, Key Trends, and Opportunities for 2025-2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the chronic inflammatory demyelinating polyneuropathy (cidp) market?
The market for chronic inflammatory demyelinating polyneuropathy (CIDP) has seen robust growth in the past few years. The forecast suggests a rise from $2.10 billion in 2024 to $2.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.4%. Factors contributing to this growth during the historical period include an aging population, enhanced treatment options, a higher level of awareness leading to early diagnosis, advances in immunology and research on autoimmune diseases, as well as an increasing prevalence of autoimmune diseases.
What will be the chronic inflammatory demyelinating polyneuropathy (cidp) market size in the future?
The market size for chronic inflammatory demyelinating polyneuropathy (CIDP) is predicted to witness substantial growth in the future years, escalating to $3.11 billion in 2029 with a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this predicted growth during the forecast period include the global aging population, an increasing focus on rare and autoimmune diseases, better access to healthcare services, initiatives for patient advocacy and awareness, and enhanced healthcare infrastructure. The upcoming trends during this period entail a rise in the occurrence of chronic inflammatory demyelinating polyneuropathy, advancements in treatment methods, escalating research and development activities, appearance of biosimilar treatment options, and the progress of personalized medicine approaches.
Get your chronic inflammatory demyelinating polyneuropathy (cidp) market report here!
What main drivers are fueling expansion in the chronic inflammatory demyelinating polyneuropathy (cidp) market?
The growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market is anticipated to be fueled by the escalating healthcare expenditure. Increased costs in healthcare are predominantly due to higher investments in medical facilities, heightened demand for sophisticated treatments, wider insurance coverage, and initiatives launched by the government to boost accessibility to healthcare. The surge in healthcare expenditure allows for access to cutting-edge treatment options, early detection, and improved management of CIDP, thereby enhancing patient outcomes and their quality of life. For instance, it was reported in May 2024, by the Office for National Statistics, a governmental department in the UK, that there was a 5.6% nominal increase in total healthcare expenditure from 2022 to 2023. This marked an impressive acceleration compared to the 0.9% growth witnessed in 2022. As such, the escalating healthcare expenditure acts as a growth driver for the chronic inflammatory demyelinating polyneuropathy (CIDP) market.
What key areas define the segmentation of the global chronic inflammatory demyelinating polyneuropathy (cidp) market?
The chronic inflammatory demyelinating polyneuropathy (CIDP) market covered in this report is segmented –
1) By Treatment: Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments
2) By Route Of Administration: Intravenous, Oral, Other Routes Of Administration
3) By Diagnosis: Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis
4) By Distribution Channel: Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics
5) By End User: Hospitals, Research Institutions, Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids, Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis, Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises, Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents, Monoclonal Antibodies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21144&type=smp
Who are the dominant players expanding their reach in the chronic inflammatory demyelinating polyneuropathy (cidp) market?
Major companies operating in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Cipla Inc., Hikma Pharmaceuticals plc, Halozyme Therapeutics, Hualan Biological Engineering Inc, argenx SE, Hovione, Nihon Pharmaceutical Co. Ltd., Bio Products Laboratory Ltd., AdvaCare Pharma.
What emerging trends are influencing the growth of the chronic inflammatory demyelinating polyneuropathy (cidp) market?
Leading firms in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) sector are concentrating on pioneering improvements such as Intravenous Immunoglobulin (IVIG) therapy. This therapy is aimed at boosting treatment efficiency, bettering patient recoveries, and offering more precise and effective immune adjustment for CIDP control. Intravenous Immunoglobulin (IVIG) therapy involves the infusion of concentrated antibodies acquired from healthy donors, utilized to control the immune system and decrease inflammation in auto-immune diseases. For example, Takeda Pharmaceutical Company Limited, a Japan-based biopharmaceutical firm, secured FDA authorization for GAMMAGARD LIQUID as an Intravenous Immunoglobulin (IVIG) treatment for adults suffering from Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in January 2024. This endorsement permits its application as an induction treatment, commencing with an initial dosage followed by sustaining dosages for long-term ailment management and enhancing neuromuscular functionality.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21144
Which regions are emerging as leaders in the chronic inflammatory demyelinating polyneuropathy (cidp) market?
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Pediatric Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report
Chickenpox Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chickenpox-vaccine-global-market-report
Stem Cell/Cord Blood Banking Global Market Report 2025
https://thebusinessresearchcompany.com/report/stem-cell-cord-blood-banking-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
